Nuvectis Pharma
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Bridge Plz N Ste 675, Fort Lee, New Je...Phone Number
(201) 614-3150Website
www.nuvectis.comRevenue
-Stock Symbol
NVCTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Nuvectis Pharma
Nuvectis Pharma Inc is a biopharmaceutical company focused on developing innovative precision medicines for the treatment of serious unmet medical needs in oncology. The company specializes in creating targeted therapies designed to address specific cancer types and patient populations. Nuvectis Pharma's drug development pipeline emphasizes novel mechanisms of action and precision medicine approaches to improve treatment outcomes for cancer patients. The company conducts clinical research and development activities to advance its therapeutic candidates through various stages of testing. Nuvectis Pharma is committed to bringing transformative cancer treatments to patients who have limited effective treatment options available.Explore more
Nuvectis Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nuvectis Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Nuvectis Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Nuvectis Pharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Nuvectis Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Nuvectis Pharma
Nuvectis Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Nuvectis Pharma launches new products
Earning: See what the market has to say on Nuvectis Pharma recently announced quarterly report
Funding: Get notified immidiatlly once Nuvectis Pharma has new funding data
Recommended Actions
Reach out to Masked Content who joined Nuvectis Pharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to Nuvectis Pharma
Compare insights from companies similar to Nuvectis Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Nuvectis Pharma
11-50
Public
$15M
2020
SS
Shay ShemeshExecutive Vice President & Development Chief & Operations Officer
Company Profile Activity
Activity Insights
Nuvectis Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nuvectis Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nuvectis Pharma.
Nuvectis Pharma financials insights
Gather financial insights about Nuvectis Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$15M
Nuvectis Pharma Tech Stack
A closer look at the technologies used by Nuvectis Pharma
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Nuvectis Pharma has introduced NXP-100, a once-daily orally administered complement factor B inhibitor currently in late-stage development, with two marketing authorization applications under review in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and ongoing clinical trials in IgA nephropathy and lupus nephritis.
Pharmaceuticals, Clinical Operations
Project
Nuvectis Pharma has two marketing authorization applications under review in China for NXP-100 in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), with Chinese approvals expected in late 2026 and early 2027, while a pivotal Phase III study in IgA nephropathy is ongoing following the successful completion of a Phase II study in that indication.
Pharmaceuticals
Project
Nuvectis Pharma has introduced NXP200, a paradox breaker BRAF inhibitor for the treatment of BRAF altered cancers, which has demonstrated single-agent activity across multiple tumor types including CNS, colorectal, and non-small cell lung cancer, and is currently in a Phase I-B study in China.
Pharmaceuticals, Clinical Operations
Partnership
Project
Partnership, Product Management, Business Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals, Manufacturing Operations
Nuvectis Pharma News & Media
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China (NMPA) for the treatment of patients with ParCiprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China (NMPA) for the treatment of patients with ParNuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)
Secondary offering priced well below previous closeNuvectis Pharma (NASDAQ:NVCT) shares dropped 25% in premarket trading on Tuesday after the clinical-stage biopharmaceutical company priced a $100 million public offering at $20. 00 per share, substantially below Monday’s closing price of $28.Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price of $20.00 per share, with expected gross proceeds to Nuvectis of $100 million. Nuvectis has also granted the u
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nuvectis Pharma
Sign Up For FreeTo access detailed company insights
Nuvectis Pharma Inc is a biopharmaceutical company focused on developing innovative precision medicines for the treatment of serious unmet medical needs in oncology. The company specializes in creating targeted therapies designed to address specific cancer types and patient populations. Nuvectis Pharma's drug development pipeline emphasizes novel m... Read More
